Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme/Isis Build Simple, No Fuss Case For Weekly Cholesterol Injectable Kynamro

Executive Summary

Genzyme and Isis are playing up mipomersen’s intrinsic qualities as they prepare to go head-to-head against Aegerion’s Juxtapid in the small homozygous familial hypercholesterolemia market. Kynamro also will carry a price tag that is $119,000 less than Juxtapid’s.

Advertisement

Related Content

Isis Says Ultra-Orphan Use Promises Speedier Approval For ISIS-APOCIIIRx
Isis Says Ultra-Orphan Use Promises Speedier Approval For ISIS-APOCIIIRx
Business News, In Brief
Deals of the Week: Ante Up For Antisense, Pharma Places Another Isis Bet
Isis Teams Up With Roche In Early-Stage Huntington’s Deal
Wary Of Surrogates, Payers Seek Outcomes Data For PCSK9 Class
Aegerion CEO Talks Juxtapid Launch, Competitive Threats At BIO
Genzyme/Isis Gear Up For Long-awaited Kynamro Launch
Disease Severity Underlies Advisory Committee Support For Kynamro
Genzyme, Isis Partner On Lipid Lowering Treatment Based On Antisense Technology

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS055085

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel